Artificial Intelligence to Advance NTCELL Production
Living Cell Technologies (ASX:LCT) is entering a new phase in its research, with artificial intelligence to be applied to the company’s groundbreaking research to combat Parkinson’s disease.
Application for Quotation of Securities - LCT
Application for quotation of securities (ASX:LCTOA) - options expiring 19 April 2024.
Living Insights Newsletter - May 2022
LCT's "Living Insights" newsletter for May 2022 provides a behind-the-scenes look at the company and our latest activities, including interviews with our new COO, Dr Belinda Di Bartolo and NZeno CEO Paul Tan.
Quarterly Activity Report and Appendix 4C
Quarterly Activity Report and Appendix 4C for the March quarter 2022, highlighted by the planned first production of NTCELL in Australia.
Chairman's Address - Extraordinary General Meeting
Chairman's address to the Extraordinary General Meeting held virtually on 28 April 2022.